Kidney Transplantation — Viva Defence

Long Case Viva Defence

The scenario

Mr K is a 52-year-old man with diabetic kidney disease who received a deceased-donor kidney transplant (donor after brain death) 6 months ago. Induction was with basiliximab; he is maintained on tacrolimus, mycophenolate and prednisolone 5 mg. His creatinine had stabilised at 130 micromol/L. He presents to the transplant clinic with a rise in creatinine to 190 micromol/L over two weeks. He feels well, is afebrile, and the graft is mildly tender. His tacrolimus trough is 9 ng/mL (target 5 to 10). The plasma BK virus PCR, ordered as part of routine surveillance, returns at 62,000 copies/mL. The CMV PCR is negative. Ultrasound shows good graft perfusion and no hydronephrosis. An allograft biopsy shows tubulointerstitial inflammation with viral inclusions positive on SV40 immunohistochemistry, with no C4d staining and no intimal arteritis. [1]

Opening statement (SASPOP)

"This is Mr K, a 52-year-old man with end-stage kidney disease from diabetic kidney disease, now six months post deceased-donor kidney transplant on tacrolimus, mycophenolate and prednisolone, presenting with a subacute rise in creatinine from 130 to 190 micromol/L, found on workup to have BK polyomavirus nephropathy — a plasma BK viral load of 62,000 copies/mL with biopsy-proven viral inclusions positive on SV40 immunohistochemistry, no C4d and no intimal arteritis to suggest concurrent antibody-mediated or T-cell mediated rejection. His main problems are the BK nephropathy, the risk of graft loss from progressive viral injury, the competing risk of rejection if I reduce immunosuppression, his cardiovascular risk profile as a diabetic transplant recipient, and the lifelong need for adherence and surveillance. My immediate priority is to reduce his immunosuppression in a structured way while monitoring the viral load and renal function, having excluded co-existing rejection." [1]

Problem list (numbered, prioritised)

1. BK polyomavirus nephropathy — biopsy-proven, with a high viral load; managed by immunosuppression reduction.
2. Graft dysfunction — creatinine 190, the consequence of the viral injury; monitor for progression.
3. The competing risk of rejection — immunosuppression reduction lowers the BK load but raises the rejection risk.
4. Diabetic cardiovascular risk — cardiovascular disease is the leading cause of death with a functioning graft.
5. The long-term surveillance agenda — skin cancer, infection, adherence, metabolic complications of immunosuppression. [1]

Integrated management plan

Pillar 1 — Reduce immunosuppression, the mainstay of BK management: "The 2024 Second International Consensus Guidelines state that the mainstay of BK nephropathy management is reduction of immunosuppression, with no evidence to support cidofovir, leflunomide, fluoroquinolones or IVIG [6]. I would reduce the mycophenolate first by 25 to 50 per cent, then, if the viral load does not fall over two to four weeks, reduce the tacrolimus towards the lower end of target. I would monitor the plasma BK viral load and the creatinine every one to two weeks, expecting the viral load to fall over four to eight weeks. I would counsel the patient that reducing immunosuppression raises the rejection risk, which is why the biopsy to exclude concurrent rejection was essential before I changed the regimen."

Pillar 2 — Exclude concurrent rejection before reducing immunosuppression: "BK nephropathy and acute rejection can coexist and mimic each other, and treating BK as rejection — escalating immunosuppression — would be catastrophic. The biopsy here shows viral inclusions with no C4d, no intimal arteritis and no donor-specific antibodies, so there is no concurrent antibody-mediated or significant T-cell mediated rejection. If the creatinine were to rise despite adequate immunosuppression reduction, I would re-biopsy to look for evolving rejection." [1]

Pillar 3 — Aggressive cardiovascular risk modification: "As a diabetic transplant recipient, his single greatest long-term threat is cardiovascular disease, the leading cause of death with a functioning graft. I would target blood pressure below 130/80, ensure he is on a statin, reinforce smoking cessation, optimise glycaemic control (noting that tacrolimus contributes to his glucose intolerance), and manage new-onset diabetes after transplant with diet, metformin if the eGFR permits, and insulin as needed." [1]

Pillar 4 — The surveillance agenda: "I would continue BK screening monthly to 9 months then quarterly to 2 years, arrange annual dermatological review (squamous cell skin cancer is 65 to 100 times more common after transplant), keep co-trimoxazole prophylaxis for Pneumocystis for the first 6 to 12 months, monitor tacrolimus troughs and the full blood count for mycophenolate marrow toxicity, and reinforce adherence at every visit." [1]

Pillar 5 — Communication: "I would explain to Mr K that his rising creatinine is caused by a virus called BK that has taken hold because his immunosuppression, which he needs to protect the kidney, has also dampened the cells that keep the virus in check. The treatment is a careful reduction of that immunosuppression, with close monitoring. I would explain the trade-off in plain language — less drug means less virus but a small extra risk of rejection — and that we will watch both closely." [1]

Probing questions the examiner would ask

Q: What is BK virus and why does it reactivate after transplant? [1]

A: "BK polyomavirus is a ubiquitous double-stranded DNA virus that infects most of the population in childhood and establishes lifelong latency in the urinary tract, particularly the renal tubular epithelium and the urothelium. It reactivates under calcineurin-inhibitor-based immunosuppression, when T-cell surveillance is suppressed, typically between month 1 and 6 post-transplant. Reactivation progresses from viruria to viraemia to nephropathy, which is why surveillance of the plasma viral load allows early intervention before graft injury is established. Risk factors include a higher intensity of immunosuppression, a tacrolimus-based regimen, prior rejection, and older recipient age [6]."

Q: Why did you biopsy before reducing the immunosuppression? [1]

A: "Because BK nephropathy and acute rejection can coexist, and the treatments pull in opposite directions — BK requires less immunosuppression, rejection requires more. Treating BK as rejection would dramatically worsen the viral infection. The biopsy confirms the diagnosis (viral inclusions positive on SV40 immunohistochemistry) and excludes concurrent rejection (no C4d, no intimal arteritis, no donor-specific antibodies), so I can confidently reduce the immunosuppression without worrying that I am undertreating rejection. The Banff schema guides this interpretation [4]."

Q: How do you distinguish BK nephropathy from acute T-cell mediated rejection on biopsy? [1]

A: "Both show tubulointerstitial inflammation, which is why they are easily confused. The discriminator is the viral inclusion: BK nephropathy shows intranuclear viral inclusions in tubular epithelial cells, confirmed by SV40 immunohistochemistry, often with a high plasma BK viral load. T-cell mediated rejection shows tubulitis and intimal arteritis (graded Banff 1A to 3) without viral inclusions. Antibody-mediated rejection is distinguished by microvascular inflammation (glomerulitis, peritubular capillaritis), C4d staining in peritubular capillaries, and donor-specific antibodies. The three diagnoses are not mutually exclusive, which is why the biopsy must be interpreted by an experienced transplant pathologist." [1]

Q: What is the standard maintenance immunosuppression regimen and why? [1]

A: "The global standard is tacrolimus plus mycophenolate plus prednisolone. The SYMPHONY study randomised recipients to standard-dose ciclosporine, low-dose ciclosporine, low-dose tacrolimus, or low-dose sirolimus, all with mycophenolate and steroid; the low-dose tacrolimus arm gave the best renal function, the lowest acute rejection rate, and the best one-year graft survival [3]. Tacrolimus is preferred over ciclosporine because it is more potent and less nephrotoxic. Mycophenolate is preferred over azathioprine because it reduces acute rejection. The regimen is started after induction with basiliximab for low to moderate risk, or anti-thymocyte globulin for high risk."

Q: What is the role of mTOR inhibitors and when would you switch to one? [1]

A: "Sirolimus and everolimus are mammalian target of rapamycin inhibitors that block T- and B-cell proliferation. I would switch from a calcineurin inhibitor to an mTOR inhibitor in two situations: first, when there is calcineurin inhibitor nephrotoxicity, to spare the kidney; and second, when a patient has recurrent or high-risk non-melanoma skin cancer, because mTOR inhibitors have anti-tumour activity and reduce skin cancer rates. I would not start an mTOR inhibitor in the early post-operative period because they impair wound healing (I would wait at least one month), and I would watch for dyslipidaemia, proteinuria, mouth ulcers, interstitial pneumonitis and marrow suppression." [1]

Q: What does a tender graft signify? [1]

A: "A tender graft is a red flag. It suggests acute rejection, pyelonephritis, renal vein thrombosis, or a perinephric collection. It is never dismissed. I would assess urgently with bloods including tacrolimus level, BK and CMV PCR, urine culture, an urgent ultrasound with Doppler to exclude obstruction or vascular thrombosis, and usually a biopsy. In Mr K's case the mild tenderness is consistent with the inflammatory BK nephropathy, but I would re-image if the pain worsened or the haemoglobin fell." [1]

Q: Cardiovascular disease is the leading cause of death with a functioning graft. How do you address this? [1]

A: "Aggressively and at every visit. I would target blood pressure below 130/80, ensure he is on a statin (almost all transplant recipients qualify on risk grounds), reinforce smoking cessation, optimise glycaemic control, encourage exercise and weight management, screen for and treat new-onset diabetes after transplant (tacrolimus and steroids are the drivers), and address his lipids. The transplanted kidney solves the uraemia but does not solve the underlying vascular disease of diabetes; in fact the immunosuppression can worsen the cardiovascular risk profile, so this agenda is central to long-term survival [1]."

Short Case Viva — Abdominal examination of a transplant recipient

Instruction: Examine this patient's abdomen. [1]

Systematic examination routine

1. End of the bed — general inspection. Note the Cushingoid appearance (facial fullness, central obesity, striae) from chronic prednisolone; the surgical scars (the transplant scar in the right or left iliac fossa; an arteriovenous fistula at the wrist or upper arm; scars from a peritoneal dialysis catheter or haemodialysis line; a parathyroidectomy scar if he had renal bone disease); the gait (a steroid myopathy or a tacrolimus neurotoxicity).
2. Hands and face — a fine tremor from tacrolimus; asterixis only if uraemic (should be absent with a functioning graft); gum hypertrophy from ciclosporin (rare on tacrolimus); oral candidiasis or viral ulcers from immunosuppression; Cushingoid facies.
3. Neck and chest — the JVP (fluid status); a working arteriovenous fistula (a thrill and a bruit) that may be preserved even after transplant; heart sounds (a flow murmur, signs of volume overload); the chest for opportunistic pneumonia.
4. Abdomen — inspect the iliac fossa transplant scar; palpate the graft (often ballotable in the iliac fossa, assess for size, consistency and tenderness); auscultate for a graft bruit (renal artery stenosis, or a normal post-operative finding); check for hepatosplenomegaly (PTLD, chronic infection); look for the fistula, the PD catheter scars and any hernias.
5. Skin — a focused skin examination for non-melanoma skin cancers (squamous cell carcinoma is the most common post-transplant malignancy), striae, bruising, eczema, and signs of the original disease (diabetic foot exam). [1]

Presentation template

"This patient has the clinical features of a renal transplant recipient. I can see a well-healed transplant scar in the right iliac fossa, a palpable graft consistent with a transplanted kidney, and a functioning brachiocephalic arteriovenous fistula at the right wrist. He has a Cushingoid appearance consistent with chronic corticosteroid therapy, and a fine tremor consistent with tacrolimus. There are no oral ulcers or gum hypertrophy. My synthesis is of a renal transplant recipient on triple immunosuppression with a functioning graft. I would like to confirm the graft function with the most recent creatinine, check the tacrolimus trough level, and review his cardiovascular risk factors, infection surveillance (BK and CMV viral loads) and malignancy surveillance (annual dermatological review)." [1]

Discussion questions

Q: What does a graft bruit signify? [1]

A: "A bruit over the graft may be a normal post-operative finding from the vascular anastomosis, or it may indicate renal artery stenosis, which typically presents weeks to months after transplant with hypertension, a rising creatinine and, classically, flash pulmonary oedema. I would investigate a clinically significant bruit with a Doppler ultrasound and, if stenosis is confirmed, treat with angioplasty with or without stenting. A new bruit with a falling haemoglobin in the early post-operative period, however, raises concern for vascular thrombosis or a pseudoaneurysm and needs urgent imaging." [1]

Q: Why might the arteriovenous fistula still be present after transplant? [1]

A: "Many units preserve a functioning fistula after a successful transplant, in case the graft fails and the patient returns to dialysis; ligating a fistula prematurely denies the patient protected vascular access. A fistula is usually only ligated if it is causing high-output cardiac failure, steal syndrome, infection, or a cosmetic problem, or if the graft has been stable for several years. Its presence in a transplant recipient is therefore a sign of good planning, not an oversight." [1]

Q: What malignancy surveillance does this patient need? [1]

A: "Annual dermatological review is mandatory, because squamous cell skin cancer is 65 to 100 times more common after transplant and is the most common post-transplant malignancy. I would also maintain age-appropriate colorectal, breast, cervical and prostate screening, and a low threshold for investigating any new symptom. Post-transplant lymphoproliferative disorder (EBV-driven, highest in EBV-seronegative recipients) presents with fever, lymphadenopathy and extranodal masses, and is managed first by reduction of immunosuppression [7]."